Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMPH NASDAQ:CRON NASDAQ:IKT NASDAQ:MRVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.58-22.7%$20.80$17.03▼$31.26$837.97M0.97468,071 shs878,061 shsCRONCronos Group$2.61+1.4%$2.59$1.84▼$3.43$980.18M0.871.38 million shs204,955 shsIKTInhibikase Therapeutics$2.06+3.3%$1.84$1.33▼$2.27$272.70M0.961.56 million shs137,738 shsMRVIMaravai LifeSciences$4.62+17.1%$3.33$1.95▼$4.83$1.19B0.621.58 million shs4.91 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.54%+9.43%+16.76%-17.87%-1.64%CRONCronos Group-1.91%-3.75%+1.98%-2.65%+38.92%IKTInhibikase Therapeutics-1.00%+5.29%+13.07%+17.06%+198,999,900.00%MRVIMaravai LifeSciences0.00%+7.07%+36.33%+25.48%+86.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPHAmphastar Pharmaceuticals$18.58-22.7%$20.80$17.03▼$31.26$837.97M0.97468,071 shs878,061 shsCRONCronos Group$2.61+1.4%$2.59$1.84▼$3.43$980.18M0.871.38 million shs204,955 shsIKTInhibikase Therapeutics$2.06+3.3%$1.84$1.33▼$2.27$272.70M0.961.56 million shs137,738 shsMRVIMaravai LifeSciences$4.62+17.1%$3.33$1.95▼$4.83$1.19B0.621.58 million shs4.91 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPHAmphastar Pharmaceuticals+0.54%+9.43%+16.76%-17.87%-1.64%CRONCronos Group-1.91%-3.75%+1.98%-2.65%+38.92%IKTInhibikase Therapeutics-1.00%+5.29%+13.07%+17.06%+198,999,900.00%MRVIMaravai LifeSciences0.00%+7.07%+36.33%+25.48%+86.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPHAmphastar Pharmaceuticals 2.00Hold$27.4347.65% UpsideCRONCronos Group 2.20Hold$2.30-11.71% DownsideIKTInhibikase Therapeutics 3.13Buy$5.50167.64% UpsideMRVIMaravai LifeSciences 2.50Moderate Buy$5.6321.89% UpsideCurrent Analyst Ratings BreakdownLatest IKT, CRON, AMPH, and MRVI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026MRVIMaravai LifeSciences Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.005/8/2026AMPHAmphastar Pharmaceuticals Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold5/8/2026MRVIMaravai LifeSciences Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$4.50 ➝ $5.504/21/2026IKTInhibikase Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026AMPHAmphastar Pharmaceuticals Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Hold$30.00 ➝ $22.004/10/2026AMPHAmphastar Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/8/2026AMPHAmphastar Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$30.00 ➝ $23.003/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/4/2026IKTInhibikase Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$4.003/2/2026CRONCronos Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)2/27/2026AMPHAmphastar Pharmaceuticals Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$34.00 ➝ $30.00(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPHAmphastar Pharmaceuticals$719.89M1.15$3.31 per share5.62$17.17 per share1.08CRONCronos Group$146.59M6.69$0.01 per share208.98$3.00 per share0.87IKTInhibikase Therapeutics$260K1,043.78N/AN/A$2.30 per share0.89MRVIMaravai LifeSciences$185.74M6.39$0.49 per share9.41$1.46 per share3.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPHAmphastar Pharmaceuticals$98.09M$2.039.275.681.9313.63%17.58%8.27%N/ACRONCronos Group-$9.45M-$0.01N/AN/AN/A-6.44%-1.12%-1.07%5/11/2026 (Estimated)IKTInhibikase Therapeutics-$48.26M-$0.48N/AN/AN/AN/A-46.90%-43.48%N/AMRVIMaravai LifeSciences-$130.77M-$0.90N/AN/AN/A-70.40%-22.79%-11.82%N/ALatest IKT, CRON, AMPH, and MRVI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CRONCronos Group$0.01N/AN/AN/A$42.20 millionN/A3/26/2026Q4 2025IKTInhibikase Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A2/26/2026Q4 2025AMPHAmphastar Pharmaceuticals$0.97$0.73-$0.24$0.51$190.48 million$183.11 million2/26/2026Q4 2025CRONCronos Group$0.01$0.02+$0.01N/A$38.51 million$58.39 million2/25/2026Q4 2025MRVIMaravai LifeSciences-$0.07-$0.04+$0.03-$0.24$49.06 million$49.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AMRVIMaravai LifeSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPHAmphastar Pharmaceuticals0.774.022.90CRONCronos GroupN/A19.5918.62IKTInhibikase TherapeuticsN/A21.7021.70MRVIMaravai LifeSciences0.856.605.69Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPHAmphastar Pharmaceuticals65.09%CRONCronos Group8.71%IKTInhibikase Therapeutics3.81%MRVIMaravai LifeSciences50.25%Insider OwnershipCompanyInsider OwnershipAMPHAmphastar Pharmaceuticals29.60%CRONCronos Group7.80%IKTInhibikase Therapeutics7.30%MRVIMaravai LifeSciences2.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPHAmphastar Pharmaceuticals1,97644.54 million31.35 millionOptionableCRONCronos Group450376.27 million346.92 millionOptionableIKTInhibikase Therapeutics6132.06 million122.42 millionN/AMRVIMaravai LifeSciences610257.07 million250.67 millionOptionableIKT, CRON, AMPH, and MRVI HeadlinesRecent News About These CompaniesWells Fargo & Company Forecasts Strong Price Appreciation for Maravai LifeSciences (NASDAQ:MRVI) Stock47 minutes ago | marketbeat.comMaravai LifeSciences (NASDAQ:MRVI) Shares Gap Up Following Analyst Upgrade1 hour ago | marketbeat.comMaravai LifeSciences Q1 Earnings Call HighlightsMay 8 at 5:08 AM | marketbeat.comMaravai LifeSciences Reports First Quarter 2026 Financial ResultsMay 7 at 11:47 PM | finance.yahoo.comMaravai LifeSciences Holdings, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 7 at 9:04 PM | seekingalpha.comMaravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue EstimatesMay 7 at 6:55 PM | zacks.comAll You Need to Know About Maravai LifeSciences (MRVI) Rating Upgrade to BuyMay 6 at 1:01 PM | zacks.comMaravai LifeSciences (NASDAQ:MRVI) vs. Glucose Health (OTCMKTS:GLUC) Financial AnalysisMay 2, 2026 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Rating of "Hold" by BrokeragesMay 1, 2026 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Average Recommendation of "Hold" by BrokeragesMay 1, 2026 | marketbeat.comBaxter International (BAX) Tops Q1 Earnings and Revenue EstimatesApril 30, 2026 | zacks.comMaravai LifeSciences (MRVI) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comMaravai LifeSciences Sees Unusually High Options Volume (NASDAQ:MRVI)April 30, 2026 | marketbeat.comMaravai LifeSciences To Host Earnings Conference Call on Thursday, May 7, 2026April 21, 2026 | timesargus.comTInvestors Purchase Large Volume of Maravai LifeSciences Put Options (NASDAQ:MRVI)April 16, 2026 | marketbeat.comMaravai LifeSciences (NASDAQ:MRVI) Sees Strong Trading Volume - Time to Buy?April 14, 2026 | marketbeat.comMaravai LifeSciences (MRVI) carrying moderately bullish sentiment despite options-linked volatilityApril 14, 2026 | msn.comHow Maravai LifeSciences (MRVI) Q4 Results Are Shaping A Cautious Valuation NarrativeApril 13, 2026 | finance.yahoo.comMaravai LifeSciences Holdings Inc.April 12, 2026 | barrons.comHow The Maravai LifeSciences (MRVI) Story Is Shifting As Analysts Rework Fair Value TargetsMarch 30, 2026 | finance.yahoo.comMaravai targets $200M–$210M 2026 revenue as restructuring drives early EBITDA turnaroundFebruary 26, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Bottom Is in for Micron Stock: 3 Signals to Buy NowBy Thomas Hughes | April 8, 2026ASML Falls Post-Earnings, Chip-Making Expansion Anchors OutlookBy Leo Miller | April 16, 2026GPU Prices Are Surging—3 Ways to Play the AI Chip ShortageBy Thomas Hughes | April 14, 2026STMicronelectronics Sends Industrial Chips Into OverdriveBy Thomas Hughes | April 24, 2026This New ETF Aims to Capitalize on Surging AI Memory Chip DemandBy Jessica Mitacek | April 13, 2026IKT, CRON, AMPH, and MRVI Company DescriptionsAmphastar Pharmaceuticals NASDAQ:AMPH$18.58 -5.45 (-22.69%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Cronos Group NASDAQ:CRON$2.60 +0.04 (+1.36%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Inhibikase Therapeutics NASDAQ:IKT$2.06 +0.07 (+3.27%) As of 11:25 AM Eastern This is a fair market value price provided by Massive. Learn more.Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.Maravai LifeSciences NASDAQ:MRVI$4.62 +0.68 (+17.13%) As of 11:26 AM Eastern This is a fair market value price provided by Massive. Learn more.Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
